CDKN2A and cancer: Additionally, given the efficacy of CDK4/6 inhibitors in certain types of cancers harboring SMARCA4 loss [66], we highlight that the deletion and nonsense variants in CDKN2A (p16) were found in 30% and 35% of our tumor samples, respectively.